In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.

The South San Francisco, Calif., biopharmaceutical company in May shut down two trials of zelnecirnon, which was being evaluated as a treatment for asthma and atopic dermatitis.

Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement, based on the FELIX trial's ...

The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the treatment of atopic dermatitis in adults and ...

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

Over the last 3 months, EPS estimates have seen 0 upward revisions and 13 downward. Revenue estimates have seen 16 upward ...

BTIG raised the firm’s price target on Apogee Therapeutics (APGE) to $100 from $81 and keeps a Buy rating on the shares. Eli Lilly (LLY) ...

which showcased the effectiveness of Ebglyss (lebrikizumab) for patients with moderate-to-severe atopic dermatitis who did not respond adequately to Dupixent. The trial results indicated that a ...

Credit: Pormezz/Shutterstock. Eli Lilly’s EBGLYSS has demonstrated improvement in skin condition and itch relief in patients with moderate-to-severe atopic dermatitis, according to new results from ...